Infectious Disease Assays

About H.U. Group Holdings

H.U. Group Holdings is a mission-driven company focused on contributing to societal health through disease prevention, early diagnosis, and treatment support. It has achieved market dominance in Japan by strategically merging entities like SRL and Fujirebio to create a fully integrated model spanning biomarker research, reagent development, and nationwide testing services. Its strategy leverages this vertical integration for quality control, innovation speed, and recurring revenue, while expanding its international footprint in high-growth diagnostic segments like oncology and neurology.

About Asuragen

Asuragen is a private, commercial-stage molecular diagnostics company that has been delivering standardized testing kits to clinical and research laboratories since its founding in 2006. The company's core business revolves around simplifying complex molecular tests, particularly in genetics and oncology, through ready-to-use kits and reagents. It operates in the growing in-vitro diagnostics (IVD) market, serving labs that require robust, reproducible assays. Asuragen's strategy is built on a portfolio of analytically validated products that aim to improve testing accessibility and efficiency.

Therapeutic Areas